Intervacc Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Intervacc wird ein Gewinn- und Umsatzwachstum von 28.5% bzw. 78.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 30.7% pro Jahr wachsen soll.

Wichtige Informationen

28.5%

Wachstumsrate der Gewinne

30.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	40.2%
Wachstumsrate der Einnahmen	78.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	20 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Jan 06

Recent updates

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Dec 15

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

Jun 01

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

May 17

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling

Feb 28

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Feb 01

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Jan 06

Is Intervacc AB (publ)'s (STO:IVACC) Shareholder Ownership Skewed Towards Insiders?

Dec 10

Gewinn- und Umsatzwachstumsprognosen

OM:IVACC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	116	-44	-32	-30	1
12/31/2025	53	-60	-47	-46	1
12/31/2024	20	-70	-60	-59	1
3/31/2024	9	-103	-54	-52	N/A
12/31/2023	8	-103	-48	-46	N/A
9/30/2023	10	-106	-57	-55	N/A
6/30/2023	10	-73	-60	-57	N/A
3/31/2023	12	-71	-65	-62	N/A
12/31/2022	12	-64	-76	-70	N/A
9/30/2022	10	-50	-70	-57	N/A
6/30/2022	10	-44	-65	-47	N/A
3/31/2022	9	-34	-55	-33	N/A
12/31/2021	9	-29	-49	-25	N/A
9/30/2021	9	-28	-43	-24	N/A
6/30/2021	8	-26	-38	-22	N/A
3/31/2021	7	-26	-36	-23	N/A
12/31/2020	7	-26	-31	-20	N/A
9/30/2020	7	-26	-35	-18	N/A
6/30/2020	8	-26	-39	-15	N/A
3/31/2020	9	-29	-45	-10	N/A
12/31/2019	14	-28	-42	-3	N/A
9/30/2019	16	-27	-40	0	N/A
6/30/2019	26	-26	-29	6	N/A
3/31/2019	41	-29	-28	0	N/A
12/31/2018	38	-27	-28	-4	N/A
9/30/2018	38	-27	-32	-12	N/A
6/30/2018	38	-24	-36	-17	N/A
3/31/2018	43	-16	-43	-28	N/A
12/31/2017	50	-13	N/A	-19	N/A
9/30/2017	52	-11	N/A	-17	N/A
6/30/2017	56	-9	N/A	-23	N/A
3/31/2017	63	-6	N/A	-1	N/A
12/31/2016	58	-7	N/A	-4	N/A
12/31/2015	65	0	N/A	-19	N/A
12/31/2014	80	9	N/A	N/A	N/A
12/31/2013	1	-2	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IVACC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IVACC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IVACC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IVACCDie Einnahmen des Unternehmens (78.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.9% pro Jahr).

Hohe Wachstumseinnahmen: IVACCDie Einnahmen des Unternehmens (78.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IVACC in 3 Jahren voraussichtlich hoch sein wird

Intervacc Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2023

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Recent updates

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) to Report Q1, 2024 Results on May 23, 2024

Intervacc AB (publ) Announces Changes in the Nomination Committee

No independent directors

Intervacc AB (publ) Announces Executive Changes

New major risk - Share price stability

Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022)

Intervacc AB (publ) Announces Composition of Nomination Committee

We're Keeping An Eye On Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022)

Intervacc AB (publ) Announces Executive Changes

Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova

Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.

Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board Member

The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months

Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 Months

First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

We Think Intervacc (STO:IVACC) Needs To Drive Business Growth Carefully

Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Intervacc AB (publ) to Report Fiscal Year 2022 Results on Apr 06, 2023

Intervacc AB (Publ) Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Intervacc AB (Publ) Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands Released

We're Not Very Worried About Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021)

Intervacc AB (Publ) Announces That Strangvac Is Now Available for Sale in the Uk

Intervacc AB (Publ) Elects Michela De Carli as Board Member At the Annual General Meeting Held on June 14, 2022

Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale in Denmark

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiveness of a Vaccine to Protect Dairy Cows Against Mastitis

We're Not Worried About Intervacc's (STO:IVACC) Cash Burn

Ntervacc AB (Publ) Announces Positive Results from A Proof-Of-Concept Study to Develop A Vaccine Against Streptococcus Suis Infection in Pigs

Full year 2021 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Intervacc AB (publ), Annual General Meeting, Jun 14, 2022

Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.S

Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key European Markets

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020)

Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against Equine Strangles, from the VMD in the UK

Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Strangles, in the EU

Independent Director Newton Aguiar has left the company

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020)

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Independent Director recently sold kr29m worth of stock

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling

New 90-day high: kr76.60

Full year 2020 earnings released: kr0.54 loss per share (vs kr0.71 loss in FY 2019)

Revenue and earnings miss expectations

Intervacc AB (publ) to Report Q2, 2021 Results on Sep 03, 2021

Intervacc AB (publ), Annual General Meeting, Jun 09, 2021

New 90-day high: kr54.80

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Is Intervacc AB (publ)'s (STO:IVACC) Shareholder Ownership Skewed Towards Insiders?

Intervacc AB (Publ) Appoints Emma Hartman as Global Product Manager for Strangvac

Third quarter 2020 earnings released: kr0.13 loss per share

Revenue and earnings miss expectations

New 90-day high: kr48.80

New 90-day high: kr40.00